4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)benzoic acid | 1375077-77-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)benzoic acid
• 英文别名: 4-[(1-hexyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]benzoic acid
• CAS: 1375077-77-2
• 化学式: C₂₃H₂₄N₂O₅
• 分子量: 408.454
• InChiKey: AXXMRDVYSRUCIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)benzoic acid 、 苯甲醇 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 以60%的产率得到benzyl 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)benzoate
  参考文献：
  名称：

  Use of quinolinone derivatives as a research tool

  摘要：

  本发明涉及使用通式（I）的喹啉酮衍生物，作为Smo受体或相关受体的配体，其靶向受体的结合位点不同于已知的配体结合位点，作为识别Smo受体或相关受体的调节剂的研究工具，表征Hedgehog信号通路和诊断的方法；本发明还涉及含有通式（I）的衍生物的试剂盒。

  公开号：

  US08957091B2
• 作为产物：
  描述：

  N-N-己基苯胺 在 三氟乙酸 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)benzoic acid
  参考文献：
  名称：

  Use of quinolinone derivatives as a research tool

  摘要：

  本发明涉及使用通式（I）的喹啉酮衍生物，作为Smo受体或相关受体的配体，其靶向受体的结合位点不同于已知的配体结合位点，作为识别Smo受体或相关受体的调节剂的研究工具，表征Hedgehog信号通路和诊断的方法；本发明还涉及含有通式（I）的衍生物的试剂盒。

  公开号：

  US08957091B2

文献信息

• Quinolinone Derivatives
  申请人：Ruat Martial

  公开号：US20130267559A1

  公开（公告）日：2013-10-10

  The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.

  本发明涉及一种通式(I)的喹啉酮衍生物化合物，能够调节干细胞和祖细胞的活性，特别是诱导其分化，这些化合物可用于治疗与干细胞分化缺陷有关的疾病；本发明还涉及这些喹啉酮衍生物中的新化合物以及含有它们的药物组合物。
• Quinolinone derivatives
  申请人：Ruat Martial

  公开号：US09061997B2

  公开（公告）日：2015-06-23

  The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.

  本发明涉及一种通式（I）的喹啉酮衍生物化合物，能够调节干细胞和祖细胞的活性，特别是诱导分化，这些化合物可用于治疗与干细胞分化缺陷相关的疾病；本发明还涉及这些喹啉酮衍生物中的新化合物以及包含它们的制药组合物。
• Use Of Quinolinone Derivatives As A Research Tool
  申请人：Ruat Martial

  公开号：US20130236912A1

  公开（公告）日：2013-09-12

  The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I).

  本发明涉及通式（I）的喹啉酮衍生物的使用，这些衍生物是Smo受体或相关受体的配体，其靶向受体的结合位点不同于已知的配体结合位点，作为研究工具用于鉴定Smo受体或相关受体的调节剂，表征Hedgehog信号通路和诊断；本发明还涉及包含上述通式（I）的衍生物的试剂盒。
• Design, synthesis and biological characterization of a new class of osteogenic (1H)-quinolone derivatives
  作者：Fabrizio Manetti、Elena Petricci、Annalisa Gabrielli、Andrè Mann、Hélène Faure、Tatiana Gorojankina、Laurent Brasseur、Lucile Hoch、Martial Ruat、Maurizio Taddei

  DOI：10.1016/j.ejmech.2016.05.062

  日期：2016.10

  Smoothened (Smo) is the signal transducer of the Hedgehog (Hh) pathway and its stimulation is considered a potential powerful tool in regenerative medicine to treat severe tissue injuries. Starting from GSA-10, a recently reported Hh activator acting on Smo, we have designed and synthesized a new class of quinolone-based compounds. Modification and decoration of three different portions of the original scaffold led to compounds able to induce differentiation of multipotent mesenchymal cells into osteoblasts. The submicromolar activity of several of these new quinolones (0.4-0.9 mu M) is comparable to or better than that of SAG and purmorphamine, two reference Smo agonists. Structure-activity relationships allow identification of several molecular determinants important for the activity of these compounds. (C) 2016 Elsevier Masson SAS. All rights reserved.
• DÉRIVÉS DE QUINOLINONE ET UTILISATION POUR TRAITER LES MALADIES CAUSÉES PAR LE DÉRÈGLEMENT DE LA FONCTION DES OSTÉOBLASTES
  申请人：Centre National de la Recherche Scientifique

  公开号：EP2640388B1

  公开（公告）日：2017-10-11